A Study to Evaluate the Safety and Efficacy of NEXAGON® (Lufepirsen Ophthalmic Gel) in Subjects With PCED
← catalyst calendarSponsored by Glaukos Corporation (industry) · GKOS — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
84estimated
Sites
28
Countries
Germany, Italy, Spain +1
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-08-17 | actual | When the study began enrolling |
| Primary completion | Dec 2025 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2025 | estimated | The whole study's end, after follow-up |
| First posted | 2023-07-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-07-24 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Persistent Corneal Epithelial Defect
Interventions
- Drug: lufepirsen high dose — also filed as NEXAGON®
- Drug: Vehicle — also filed as Placebo
- Drug: lufepirsen low dose — also filed as NEXAGON®
Primary outcome
what the primary-completion date above is the date OFAchieve Corneal Re-epithelialization Including Durability (CRC)
measured End of Study: 28 Days after achieving re-epithelialization
Permalink · GKOS's whole pipeline · Catalyst calendar · Every registered study · What changed